Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04204434 · ClinicalTrials.gov registry record
Biomarkers For Immune Checkpoint Inhibitors
A clinical trial of Neoplasms and Advanced Cancer, sponsored by Rhode Island Hospital.
- Completed
- Registry status
- 119
- Enrollment target
- 2
- Study locations
NCT04204434: Completed study of Neoplasms and Advanced Cancer, sponsored by Rhode Island Hospital.
NCT04204434 is a study of Neoplasms and Advanced Cancer that has completed, run by Rhode Island Hospital. The registered enrollment target is 119 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04204434, a study of Neoplasms and Advanced Cancer, has completed, sponsored by Rhode Island Hospital.
- COMPLETED
- Registry status
- 119 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a laboratory, non-treatment study. Immune checkpoint inhibitors are a type of immunotherapy that stimulates a patients immune system to fight their cancer. Immune checkpoint inhibitors are standard, FDA approved treatment for certain types of cancers such as melanoma, lung cancer, kidney cancer and bladder cancer. The laboratories of Dr. Jack Elias and Dr. Chun Geun Lee at Brown University are studying how immune checkpoint inhibitors work.Kintai Therapeutics is a biotech company in Cambridge Massachusetts that will focus on the molecules present in the GI tract, including the stomach, small intestine and colon.
Primary Outcome
Measure biomarker levels of immune checkpoint inhibitors in blood serum
Conditions Studied
Study Locations (2)
Rhode Island
- Rhode Island Hospital - Providence
- The Miriam Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2016-11-29 |
| Est. Completion | 2024-04-26 |
What the finished NCT04204434 record still lists
NCT04204434 is an observational study that tracks outcomes without assigning an intervention. The registered 119 participants enrollment target is mid-sized for trials with a published cap, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Neoplasms appearing as the primary indexed condition, and to 0 interventions.
NCT04204434 reports a single indexed study location in Rhode Island.
Frequently Asked Questions
What is clinical trial NCT04204434 about?
NCT04204434 is a clinical study titled "Biomarkers For Immune Checkpoint Inhibitors". This is a laboratory, non-treatment study. Immune checkpoint inhibitors are a type of immunotherapy that stimulates a patients immune system to fight their cancer. Immune checkpoint inhibitors are standard, FDA approved treatment for certain types of cancers such as melanoma, lung cancer, kidney can...
What is the current status of trial NCT04204434?
This trial is currently completed. The enrollment target is 119 participants. The study started on 2016-11-29. Estimated completion is 2024-04-26.
What conditions does trial NCT04204434 study?
This clinical trial studies the following conditions: Neoplasms, Advanced Cancer.
Who is sponsoring clinical trial NCT04204434?
This trial is sponsored by Rhode Island Hospital, which has 130 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04204434 being conducted?
This trial has 2 study locations across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04204434's enrollment target sits among peer trials
119 67th of 158 higher than 92 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
Real World Registry for Use of the Ion Endoluminal System
RECRUITING
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Endometrial Cell Collection With the PadKit
RECRUITING · NA
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Resilience in East Asian Immigrants for Advance Care Planning Discussions
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04870762 · 119 participants · Phase 2
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
- NCT05559853 · 119 participants
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
- NCT06564389 · 119 participants · Phase 1
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- NCT06742801 · 119 participants · NA
Onyx™ Liquid Embolic IDE Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI